Detalhe da pesquisa
1.
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
J Neurol Neurosurg Psychiatry;
94(1): 23-30, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36171104
2.
Disability accrual in primary and secondary progressive multiple sclerosis.
J Neurol Neurosurg Psychiatry;
94(9): 707-717, 2023 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37068931
3.
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Mult Scler;
29(1): 119-129, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35894247
4.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Mult Scler;
29(7): 875-883, 2023 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36851894
5.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
J Neurol Neurosurg Psychiatry;
93(12): 1330-1337, 2022 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36261289
6.
Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS.
Mult Scler;
28(11): 1752-1761, 2022 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35373638
7.
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Mult Scler;
28(6): 958-969, 2022 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34623947
8.
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.
Eur J Neurol;
29(8): 2321-2334, 2022 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35582938
9.
Determinants of therapeutic lag in multiple sclerosis.
Mult Scler;
27(12): 1838-1851, 2021 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33423618
10.
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis.
Mult Scler;
27(5): 755-766, 2021 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32538713
11.
Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
Brain;
143(9): 2742-2756, 2020 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32947619
12.
Risk of secondary progressive multiple sclerosis: A longitudinal study.
Mult Scler;
26(1): 79-90, 2020 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31397221
13.
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
J Neurol Neurosurg Psychiatry;
90(4): 458-468, 2019 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30636699
14.
Cladribine versus fingolimod, natalizumab and interferon ß for multiple sclerosis.
Mult Scler;
24(12): 1617-1626, 2018 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28857680
15.
A Delphi-Based Consensus Statement on the Management of Anticoagulated Patients With Botulinum Toxin for Limb Spasticity.
Arch Phys Med Rehabil;
99(11): 2183-2189, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29803825
16.
Contribution of different relapse phenotypes to disability in multiple sclerosis.
Mult Scler;
23(2): 266-276, 2017 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27055805
17.
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
J Neurol;
271(1): 472-485, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37768389
18.
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
JAMA Neurol;
80(7): 739-748, 2023 07 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37273217
19.
Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Front Neurol;
14: 1274194, 2023.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38187157
20.
1-Fluoro-3,3-dimethyl-1,3-dihydro-1λ(3)-benzo[d][1,2]iodoxole.
Acta Crystallogr Sect E Struct Rep Online;
68(Pt 4): o1238, 2012 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22606171